Sickle Cell Anemia Testing & Screening Market - Global Forecast 2026-2032

The Sickle Cell Anemia Testing & Screening Market size was estimated at USD 437.40 million in 2025 and expected to reach USD 475.14 million in 2026, at a CAGR of 9.12% to reach USD 806.26 million by 2032.

Sickle cell anemia testing and screening sit at the intersection of newborn health, genetic diagnostics, hematology care, and population-level prevention. Sickle cell disease is one of the most common inherited blood disorders worldwide, driven by pathogenic variants in the HBB gene that affect hemoglobin structure and red blood cell function. The World Health Organization has long identified sickle cell disease as a major public health concern, particularly across sub-Saharan Africa, India, the Middle East, the Mediterranean basin, and populations with African, Middle Eastern, South Asian, Caribbean, and Latin American ancestry.

The testing ecosystem includes newborn screening, carrier screening, prenatal testing, confirmatory hemoglobin analysis, molecular diagnostics, and point-of-care testing. Established laboratory methods such as high-performance liquid chromatography, isoelectric focusing, capillary electrophoresis, hemoglobin electrophoresis, and DNA-based assays remain central to diagnosis. Demand is being shaped by expanded newborn screening mandates, migration-driven changes in disease distribution, greater awareness of reproductive carrier testing, and the need for earlier treatment initiation with penicillin prophylaxis, vaccination, hydroxyurea, transfusion programs, and curative pathways such as stem cell transplantation and emerging gene therapies.

The landscape is shifting from symptom-led diagnosis toward early, preventive, and genetically informed screening. Universal newborn screening in countries such as the United States has shown that early identification can reduce childhood morbidity and mortality when linked to comprehensive care. In contrast, many high-burden countries continue to face gaps in laboratory capacity, confirmatory testing, referral pathways, and long-term care continuity.

A second major shift is the movement of testing closer to the patient. Point-of-care tests are gaining attention for low-resource and rural settings because they can shorten time to diagnosis and reduce loss to follow-up. At the same time, molecular testing is becoming more important for carrier detection, prenatal counseling, complex genotype confirmation, and eligibility assessment for advanced therapies. These changes are increasing the value of integrated screening programs that combine diagnostics, counseling, treatment access, registry development, and quality assurance.

Artificial intelligence is beginning to add cumulative value across sickle cell anemia testing and screening, particularly in laboratory workflow optimization, image-supported hematology review, variant interpretation support, risk prediction, and population health surveillance. AI-enabled analytics can help prioritize abnormal screening results, flag incomplete follow-up, support quality control, and identify geographic areas where carrier screening or newborn screening coverage is low.

The most immediate opportunity is not replacing validated diagnostic methods but strengthening speed, consistency, and decision support. AI models require representative datasets, clinical validation, transparent governance, and careful monitoring for bias because sickle cell disease disproportionately affects historically underserved populations. When applied responsibly, AI can improve screening program efficiency, reduce diagnostic delays, and help health systems move from reactive care to proactive, risk-stratified management.

Asia-Pacific presents a mixed screening environment. India carries one of the world’s largest sickle cell disease burdens, with high prevalence among several tribal and rural communities, while China, Japan, South Korea, and Australia have more targeted demand linked to migration, carrier identification, prenatal testing, and specialized hematology services. National and state-level initiatives in India are increasing attention to population screening, confirmatory diagnostics, and linkage to care.

North America remains one of the most mature markets due to universal newborn screening, established confirmatory testing networks, and clinical guidelines from organizations such as the CDC, NIH, and professional hematology societies. Latin America is increasingly important because Brazil and parts of the Caribbean and Central America have sizable populations at risk, creating demand for newborn screening expansion and equitable access to hematology care. Europe benefits from advanced laboratory infrastructure and newborn screening programs in several countries, although policy coverage differs across member states. The Middle East has strong relevance because consanguinity and regional hemoglobinopathy prevalence support premarital, carrier, and prenatal screening programs. Africa represents the highest public health need, with sub-Saharan Africa accounting for the largest share of global births affected by sickle cell disease and requiring scalable newborn and point-of-care screening linked to treatment access.

ASEAN countries show rising demand for hemoglobinopathy screening because beta-thalassemia and hemoglobin variants often coexist in regional diagnostic workflows; sickle cell demand is more targeted but increasingly relevant in mobile and diverse populations. GCC countries are notable for premarital and genetic screening frameworks, with sickle cell disease particularly relevant in Saudi Arabia, Bahrain, Oman, and parts of the Gulf where carrier detection and counseling are public health priorities.

The European Union supports advanced diagnostic adoption through strong laboratory networks, newborn screening policy development, and cross-border rare disease collaboration, although implementation varies by country. BRICS countries are highly significant because India, Brazil, South Africa, China, and Russia together combine high population scale, large public health systems, and diverse sickle cell testing needs. G7 countries lead in advanced molecular diagnostics, reimbursement capacity, and specialty care integration, while NATO countries collectively reflect a combination of mature laboratory infrastructure, migration-linked screening demand, and military-family health system considerations.

The United States has a well-established newborn screening system and the CDC estimates that sickle cell disease affects about 100,000 Americans, with higher prevalence among Black or African American and Hispanic populations. Canada’s screening environment is province-driven, while Mexico and Brazil face growing needs for equitable newborn screening and confirmatory testing, with Brazil maintaining one of Latin America’s most important sickle cell care ecosystems.

In Europe, the United Kingdom, France, Germany, Italy, and Spain are shaped by migration patterns, established laboratory medicine capabilities, and expanding newborn or targeted screening approaches. Russia has more limited sickle cell demand compared with thalassemia and other hematologic priorities. In Asia-Pacific, India is a strategic priority due to large affected populations, while China, Japan, Australia, and South Korea are characterized by advanced diagnostics capacity, targeted screening, and demand from migrant or at-risk communities.

Industry leaders should prioritize solutions that shorten the interval between screening, confirmation, counseling, and treatment initiation. This requires validated assays, robust quality control, interoperable reporting, and partnerships with newborn screening laboratories, public health agencies, hospitals, and community organizations serving high-risk populations.

Diagnostic companies should expand affordable point-of-care and molecular testing portfolios while maintaining alignment with clinical guidelines and regulatory expectations. Health systems should invest in registry-enabled follow-up, genetic counseling capacity, and culturally competent education. Public-private collaborations can improve screening coverage in high-burden regions by combining reagent access, workforce training, sample transport systems, digital reporting, and patient navigation.

This executive summary is based on a structured review of publicly available and evidence-based sources, including guidance and data from the World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, national newborn screening programs, peer-reviewed hematology literature, regulatory publications, and public health policy documents.

The methodology emphasizes triangulation across epidemiology, diagnostic technology adoption, screening policy, reimbursement context, and regional health system capacity. Insights were assessed for consistency, clinical relevance, and applicability to sickle cell anemia testing and screening across newborn, carrier, prenatal, confirmatory, and point-of-care use cases.

Sickle cell anemia testing and screening are moving from isolated diagnostic events toward integrated, lifelong care pathways. The strongest opportunities are emerging where newborn screening, confirmatory testing, genetic counseling, digital follow-up, and access to evidence-based treatment are connected through coordinated systems.

The future of the market will be shaped by equitable screening coverage, reliable laboratory infrastructure, responsible AI adoption, and affordable technologies that work in both advanced and resource-constrained settings. Organizations that align innovation with public health impact will be best positioned to improve outcomes for individuals and families affected by sickle cell disease.